Table 1.
Characteristics of cases and controls exposed to glipizide or glyburide on the index date in pharmacoepidemiologic studies
| Glipizide | Glyburide | |||||
|---|---|---|---|---|---|---|
| Cases | Controls | Matched OR (95% CI) | Cases | Controls | Matched OR (95% CI) | |
| Variable | n = 5,784 | N = 289,965 | n = 7,693 | n = 384,867 | ||
| Age | ||||||
| 18–50 years | 979 (16.9%) | 54 300 (18.7%) | Reference | 952 (12.4%) | 65 540 (17.0%) | Reference |
| 50–60 years | 937 (16.2%) | 52 753 (18.2%) | 0.98 (0.90, 1.08) | 1109 (14.4%) | 67 111 (17.4%) | 1.14 (1.04, 1.24) |
| 60–70 years | 1132 (19.6%) | 65 574 (22.6%) | 0.96 (0.88, 1.05) | 1576 (20.5%) | 90 223 (23.4%) | 1.21 (1.11, 1.31) |
| 70–80 years | 1437 (24.8%) | 68 226 (23.5%) | 1.17 (1.08, 1.27) | 2104 (27.4%) | 96 520 (25.1%) | 1.52 (1.40, 1.64) |
| ≥80 years | 1299 (22.5%) | 49 112 (16.9%) | 1.49 (1.37, 1.62) | 1952 (25.4%) | 65 473 (17.0%) | 2.10 (1.94, 2.27) |
| Gender, male | 1842 (31.8%) | 97 839 (33.7%) | 0.92 (0.87, 0.97) | 2430 (31.6%) | 129 812 (33.7%) | 0.91 (0.86, 0.95) |
| Race | ||||||
| Caucasian | 2102 (36.3%) | 118 569 (40.9%) | Reference | 2918 (37.9%) | 158 652 (41.2%) | Reference |
| African American | 1608 (27.8%) | 51 468 (17.8%) | 1.78 (1.67, 1.91) | 1716 (22.3%) | 59 034 (15.3%) | 1.60 (1.50, 1.70) |
| Hispanic | 1089 (18.8%) | 63 178 (21.8%) | 0.95 (0.88, 1.03) | 1530 (19.9%) | 85 525 (22.2%) | 0.96 (0.90, 1.03) |
| Other/unknown | 985 (17.0%) | 56 750 (19.6%) | 0.96 (0.88, 1.04) | 1529 (19.9%) | 81 656 (21.2%) | 1.00 (0.94, 1.07) |
| Number of prior glipizide prescriptions | ||||||
| 0 | 629 (10.9%) | 12 601 (4.4%) | 2.83 (2.60, 3.09) | 881 (11.4%) | 16 352 (4.2%) | 3.06 (2.84, 3.29) |
| 1 | 355 (6.1%) | 12 807 (4.4%) | 1.58 (1.42, 1.77) | 420 (5.5%) | 16 214 (4.2%) | 1.48 (1.34, 1.64) |
| 2 | 304 (5.3%) | 13 469 (4.6%) | 1.30 (1.15, 1.46) | 385 (5.0%) | 17 184 (4.5%) | 1.28 (1.15, 1.43) |
| ≥3 | 4496 (77.7%) | 251 088 (86.6%) | Reference | 6007 (78.1%) | 335 117 (87.1%) | Reference |
| Dementia | 1362 (23.6%) | 38 182 (13.2%) | 2.13 (2.00, 2.27) | 1824 (23.7%) | 46 473 (12.1%) | 2.37 (2.24, 2.50) |
| Kidney disease | 1275 (22.0%) | 24 716 (8.5%) | 3.10 (2.91, 3.31) | 1289 (16.8%) | 25 916 (6.7%) | 2.82 (2.65, 2.99) |
| Use of insulin | 1066 (18.4%) | 21 790 (7.5%) | 2.82 (2.63, 3.02) | 1024 (13.3%) | 25 798 (6.7%) | 2.15 (2.01, 2.30) |
| Fibrate | ||||||
| Fenofibrate | 20 (0.4%) | 1 353 (0.5%) | 0.74 (0.48, 1.15) | 47 (0.6%) | 1 772 (0.5%) | 1.33 (0.99, 1.78) |
| Gemfibrozil | 53 (0.9%) | 2 474 (0.8%) | 1.07 (0.82, 1.41) | 81 (1.0%) | 3 417 (0.9%) | 1.19 (0.95, 1.48) |
| Statin | ||||||
| Atorvastatin | 417 (7.2%) | 25 019 (8.6%) | 0.82 (0.74, 0.91) | 566 (7.4%) | 32 099 (8.3%) | 0.87 (0.80, 0.95) |
| Fluvastatin | 21 (0.4%) | 1 606 (0.6%) | 0.66 (0.43, 1.01) | 31 (0.4%) | 2 377 (0.6%) | 0.65 (0.46, 0.93) |
| Lovastatin | 27 (0.5%) | 1 714 (0.6%) | 0.78 (0.53, 1.15) | 36 (0.5%) | 2 288 (0.6%) | 0.78 (0.56, 1.09) |
| Simvastatin | 173 (3.0%) | 8 613 (3.0%) | 1.01 (0.86, 1.18) | 252 (3.3%) | 12 163 (3.2%) | 1.04 (0.91, 1.18) |
| Pravastatin | 91 (1.6%) | 5 226 (1.8%) | 0.87 (0.71, 1.07) | 134 (1.7%) | 8 337 (2.2%) | 0.80 (0.67, 0.95) |